You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
TOKYO, August 7, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) confirms it has submitted a New Drug Application (NDA) to Japan's Ministry of Health,...
View Q1/FY2026 Financial results and related materials.
- First and only treatment regimen for adults with MIBC, regardless of cisplatin eligibility, representing a platinum-free potential standard of care - - Broadened approval supported by Phase 3...
TOKYO, July 7, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the Center for Drug Evaluation (CDE) of the China National Medical...
- Approval based on Phase 3 EV-303 results demonstrating significant improvements in event-free survival and overall survival compared with surgery alone - - Despite curative-intent surgery,...
Follow us
